Hepatitis B virus infection and fatty liver in the general population

Wong, Vincent Wai‐Sun; Wong, Grace Lai–Hung; Chu, Winnie Chiu-Wing; Chim, Angel Mei‐Ling; Ong, A. S. H.; Yeung, David W. K.; Yiu, Karen Kar–Lum; Chu, Shumo; Chan, Hoi–Yun; Woo, Jean; Chan, Francis K.L.; Chan, Henry Lik‐Yuen

doi:10.1016/j.jhep.2011.09.013

Cited by 206 publications

(234 citation statements)

References 55 publications

Supporting

Mentioning

205

Contrasting

Unclassified

Order By: Relevance

“…Chronic HBV infection is associated with lower prevalence of hypertriglyceridemia in men and women (Jan et al 2006;Chen et al 2010;Wong et al 2012;Chung et al 2014;Huang et al 2016). In this study, however, OBI was detected at higher frequency in HLP patients than in replacement blood donor population controls (9.5% vs. 2.4%, P < 0.001), which suggested a positive association between OBI and HLP.…”

Section: Discussioncontrasting

confidence: 67%

See 1 more Smart Citation

Occult Hepatitis B Virus Infection in Hyperlipidemia Patients

Yang

Li²,

Li³

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection is associated with lower prevalence of hyperlipidemia (HLP).However, occult HBV infection (OBI) in HLP patients has not yet been explored. OBI is defined as the presence of detectable HBV DNA in serum or liver tissue but undetectable HBV surface antigen in serum. In this study, 1,036 HLP patients and 1,134 replacement blood donor controls were recruited. Among them, 252 HLP patients and 255 blood donors with antibody to HBV core positive were selected and analyzed. HBV DNA was confirmed by nucleic acid testing assays, and nucleotide mutations were analyzed. OBI was detected in 9.5% (24/252) of HLP patients and 2.4% (6/255) of blood donors, respectively (P < 0.001). In HLP population, 41.7% of OBI and 13.6% of non-OBI carriers were associated with daily alcohol consuming > 30 g/day (P < 0.01), while in control population those rates were not statistically different between OBI and non-OBI carriers (P > 0.05). Viral load of OBI in HLP patients was higher than that of OBI in blood donors (P < 0.05), which was a positive correlation between total cholesterol and HBV viral load levels (r = 0.474 P = 0.019). HBV vaccination rate was found significantly lower in OBI HLP patients than that in non-OBI HLP patients (P < 0.01). Importantly, mutations were found in basic core promoter region of HBV among OBI HLP patients. In conclusion, the frequency of OBI is significantly higher in HLP patients, especially those patients with heavy daily alcohol consumption.

show abstract

Section: Discussioncontrasting

confidence: 67%

“…Previous studies showed that chronic hepatitis B virus (HBV) infection was associated with lower prevalence of hypertriglyceridemia (Jan et al 2006;Chen et al 2010;Wong et al 2012;Chung et al 2014;Huang et al 2016) or hypercholesterolemia (Chen et al 2010;Liu et al 2013). …”

Section: Introductionmentioning

confidence: 99%

Occult Hepatitis B Virus Infection in Hyperlipidemia Patients

Yang

Li²,

Li³

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Despite studies that claim an increase in NAFLD in the presence of active viral replication in patients with chronic HBV infection, there are studies that report suppression of viral replication in NAFLD (9,10). Many epidemiological studies have reported no difference regarding HBV replication between patients with NAFLD and those without NAFLD (3)(4)(5)(6)8,(10)(11)(12)(13). However, a negative correlation between NAFLD and serum HBV DNA levels has also been reported in a meta-analysis (7).…”

Section: Introductionmentioning

confidence: 99%

Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir

Ceylan

Arslan²,

Batırel³

et al. 2016

Turk J Gastroenterol

View full text Add to dashboard Cite

“…[20] Current guidelines, therefore, recommend that the most potent drugs with optimal resistance profiles (ie, entecavir [ETV] and tenofovir disoproxil fumarate [TDF]) should be used as first-line monotherapies in CHB. [20][21][22][23][24] These two agents were approved by the US No clear evidence exists regarding the termination of the prophylactic administration of antiviral drugs. K. Ono et al lead clinical example, when the premature cancellation of lamivudine resulted in a re-HBV infection reactivation.…”

Section: Introductionmentioning

confidence: 99%

Association of Chronic HBV Infection with Chronic Lymphoproliferative Disorders: A Review and Case Report

Sleptsovа¹,

Yadrichinskaya²,

Palchina³

et al. 2016

Int J Biomed

View full text Add to dashboard Cite

This article presents a clinical report on the associated course of chronic hepatitis B virus (HBV) infection with Castleman's disease (CD). We noticed the reactivation of previously latent chronic hepatitis B (CHB) with high replicative activity of HBV DNA during the treatment of lymphoproliferative disease. This clinical case dictates the need for pre-emptive therapy of HBV infection with nucleoside analogues in patients who are receiving chemotherapy. (Int J Biomed. 2016;6(2):128-132.).

show abstract

Hepatitis B virus infection and fatty liver in the general population

Cited by 206 publications

References 55 publications

Occult Hepatitis B Virus Infection in Hyperlipidemia Patients

Occult Hepatitis B Virus Infection in Hyperlipidemia Patients

Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir

Association of Chronic HBV Infection with Chronic Lymphoproliferative Disorders: A Review and Case Report

Contact Info

Product

Resources

About